BioNTech R&D Austria, a wholly owned subsidiary of BioNTech SE since October 2021, is a research hub within the BioNTech Group specializing in the development of new anti-bacterial agents. At the site in Vienna, Austria, a team of approximately 20 scientists research and develop precision therapies against bacterial infections.
R&D:The research hub resulted from the acquisition of PhagoMed, a Viennese biotech that has been developing pathogen-specific lysin-based antimicrobials since 2018. The core of the technology platform is the LysinBuilder™, a platform for in-silico prediction and pharmaceutical development of synthetic lysins. Lysins are proteins that specifically cut the cell wall of individual bacterial genera, killing the bacterial cells.